SCIENTIFIC TALK AMD | 11 ottobre 2022 | ore 17
Leggi
Rationale and design of the phase 3 development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
Philis-Tsimikas A, Bajaj HS, Begtrup K, et al.
Diabetes Obes Metab. Pub. online 15 Sep 2022
Leggi
Effects of empagliflozin in women and men with heart failure and preserved ejection fraction
Butler J, Filippatos G, Siddiqi TJ, et al.
Circulation. 2022 Sep 13;101161CIRCULATIONAHA122059755
Leggi
Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF
Selvaraj S, Fu Z, Jones P, et al.
Circulation. 2022;146(11):808-818
Leggi
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies MJ, Aroda VR, Collins BS et al.
Diabetologia. Pub. online 24 September 2022.
Leggi
SCIENTIFIC TALK AMD – FAD L’EVOLUZIONE DELLA TERAPIA DEL DMT2: DOPPIO AGONISTA GIP/GLP1
Dopo il debutto del primo Scientific Talk AMD “Fisiopatologia dell’asse incretinico e meccanismo d’azione degli agonisti recettoriali multipli”, l’esperienza prosegue con il percorso di formazione a distanza. Invitiamo tutti coloro che non sono riusciti a partecipare alla prima diretta o sono interessati ad approfondire a seguire il percorso disponibile a…
Leggi
Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study
Liao LD, Ferrara A, Greenberg MB, et al.
BMC Med. 2022;20(1):307.
Leggi
The associations of mean glucose and time-in-range from continuous glucose monitoring with HbA1c in adults with type 2 diabetes
Selvin E, Wang D, Rooney MR, et al.
Diabetes Technol Ther. Pub. online 15 Sep 2022.
Leggi
Differential contribution of alpha and beta cell dysfunction to impaired fasting glucose and impaired glucose tolerance
Kohlenberg JD, Laurenti MC, Egan AM et al
Diabetologia. Pub. online 16 Sep 2022.
Leggi